Securities
Sep. 22, 2012
Pharmaceuticals see wave of securities fraud litigation
A recent decision is yet another example of how statements by pharmaceutical companies about clinical trials consistently give rise to securities litigation. By Christopher H. McGrath and Rebecca L. Eggleston of Paul Hastings LLP
This month, the 9th Circuit decided In re Rigel Pharmaceuticals, Inc. Securities Litigation, and offered protection for pharmaceutical companies from fraud claims by plaintiffs who allege that different statistical methodologies should have been used in conducting clinical trials. 2012 DJDAR 12584 (9th Cir. Sept. 6, 2012). The decision is another recent example of how statements by pharmaceutical and biote...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In